Literature DB >> 33509564

Effect of Medicaid Expansions on HIV Diagnoses and Pre-Exposure Prophylaxis Use.

Bita Fayaz Farkhad1, David R Holtgrave2, Dolores Albarracín3.   

Abstract

INTRODUCTION: Increased insurance coverage and access to health care can increase identification of undiagnosed HIV infection and use of HIV prevention services such as pre-exposure prophylaxis. This study investigates whether the Medicaid expansions facilitated by the Affordable Care Act had these effects.
METHODS: A difference-in-differences design was used to estimate the effects of the Medicaid expansions using data on HIV diagnoses per 100,000 population, awareness of HIV status, and pre-exposure prophylaxis use. The analyses involved first calculating differences in new diagnoses and pre-exposure prophylaxis use before and after the expansions and then comparing these differences between treatment counties (i.e., all counties in states that expanded Medicaid) and control counties (i.e., all counties in states that did not expand Medicaid). Further analyses to investigate mechanisms addressed associations with HIV incidence, rates of sexually transmitted infections, and substance use. Analyses were conducted between August 2019 and July 2020.
RESULTS: Medicaid expansions were associated with an increase in HIV diagnoses of 0.508 per 100,000 population, or 13.9% (p=0.037), particularly for infections contracted via injection drug use and among low-income, rural counties with a high share of pre-Affordable Care Act uninsured rates that were most likely to be affected by the expansions. In addition, Medicaid expansions were associated with improvements in the knowledge of HIV status and pre-exposure prophylaxis use. There was no impact of the expansions on incident HIV, substance use, or sexually transmitted infection rates with the exception of gonorrhea, which decreased after the expansions. Altogether, these results suggest that the changes in new HIV diagnoses, awareness of HIV status, and pre-exposure prophylaxis were not simply because of a higher incidence or an increase in infection risk.
CONCLUSIONS: Medicaid expansions were associated with increases in the percentage of people living with HIV who are aware of their status and pre-exposure prophylaxis use. Expanding public health insurance may be an avenue for curbing the HIV epidemic.
Copyright © 2020 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33509564      PMCID: PMC7903489          DOI: 10.1016/j.amepre.2020.10.021

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  25 in total

1.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

Authors:  Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden
Journal:  N Engl J Med       Date:  2010-11-23       Impact factor: 91.245

2.  HIV in the United States: Getting to Zero Transmissions by 2030.

Authors:  Ingrid Katz; Ashish K Jha
Journal:  JAMA       Date:  2019-03-26       Impact factor: 56.272

3.  HIV Viral Load and Transmissibility of HIV Infection: Undetectable Equals Untransmittable.

Authors:  Robert W Eisinger; Carl W Dieffenbach; Anthony S Fauci
Journal:  JAMA       Date:  2019-02-05       Impact factor: 56.272

4.  Is Insurance a Barrier to HIV Preexposure Prophylaxis? Clarifying the Issue.

Authors:  Emma Sophia Kay; Rogério M Pinto
Journal:  Am J Public Health       Date:  2019-11-14       Impact factor: 9.308

5.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.

Authors:  Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

6.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

Authors:  Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton
Journal:  N Engl J Med       Date:  2015-07-20       Impact factor: 91.245

7.  A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.

Authors:  Christine Danel; Raoul Moh; Delphine Gabillard; Anani Badje; Jérôme Le Carrou; Timothée Ouassa; Eric Ouattara; Amani Anzian; Jean-Baptiste Ntakpé; Albert Minga; Gérard M Kouame; Franck Bouhoussou; Arlette Emieme; Antoine Kouamé; André Inwoley; Thomas-d'Aquin Toni; Hugues Ahiboh; Mathieu Kabran; Cyprien Rabe; Baba Sidibé; Gustave Nzunetu; Romuald Konan; Joachim Gnokoro; Patrice Gouesse; Eugène Messou; Lambert Dohoun; Synali Kamagate; Abo Yao; Solange Amon; Amadou-Barenson Kouame; Aboli Koua; Emmanuel Kouamé; Yao Ndri; Olivier Ba-Gomis; Marcelle Daligou; Simplice Ackoundzé; Denise Hawerlander; Alex Ani; Fassery Dembélé; Fatoumata Koné; Calixte Guéhi; Constance Kanga; Serge Koule; Jonas Séri; Mykayila Oyebi; Nathalie Mbakop; Olewole Makaila; Carole Babatunde; Nathanael Babatounde; Gisèle Bleoué; Mireille Tchoutedjem; Alain-Claude Kouadio; Ghislaine Sena; Sahinou-Yediga Yededji; Rodrigue Assi; Alima Bakayoko; Alassane Mahassadi; Alain Attia; Armel Oussou; Max Mobio; Doféré Bamba; Mesmin Koman; Apollinaire Horo; Nina Deschamps; Henri Chenal; Madeleine Sassan-Morokro; Seidou Konate; Kakou Aka; Eba Aoussi; Valérie Journot; Célestin Nchot; Sophie Karcher; Marie-Laure Chaix; Christine Rouzioux; Papa-Salif Sow; Christian Perronne; Pierre-Marie Girard; Hervé Menan; Emmanuel Bissagnene; Auguste Kadio; Virginie Ettiegne-Traore; Corinne Moh-Semdé; Abo Kouame; Jean-Marie Massumbuko; Geneviève Chêne; Mireille Dosso; Serge K Domoua; Thérèse N'Dri-Yoman; Roger Salamon; Serge P Eholié; Xavier Anglaret
Journal:  N Engl J Med       Date:  2015-07-20       Impact factor: 91.245

8.  Effect of early versus deferred antiretroviral therapy for HIV on survival.

Authors:  Mari M Kitahata; Stephen J Gange; Alison G Abraham; Barry Merriman; Michael S Saag; Amy C Justice; Robert S Hogg; Steven G Deeks; Joseph J Eron; John T Brooks; Sean B Rourke; M John Gill; Ronald J Bosch; Jeffrey N Martin; Marina B Klein; Lisa P Jacobson; Benigno Rodriguez; Timothy R Sterling; Gregory D Kirk; Sonia Napravnik; Anita R Rachlis; Liviana M Calzavara; Michael A Horberg; Michael J Silverberg; Kelly A Gebo; James J Goedert; Constance A Benson; Ann C Collier; Stephen E Van Rompaey; Heidi M Crane; Rosemary G McKaig; Bryan Lau; Aimee M Freeman; Richard D Moore
Journal:  N Engl J Med       Date:  2009-04-01       Impact factor: 91.245

9.  Uptake of HIV testing in substance use disorder treatment programs that offer on-site testing.

Authors:  Tiffany L Kyle; Viviana E Horigian; Susan Tross; Valerie A Gruber; Margaret Pereyra; Raul N Mandler; Daniel J Feaster; Lisa R Metsch
Journal:  AIDS Behav       Date:  2015-03

10.  Vital Signs: Human Immunodeficiency Virus Testing and Diagnosis Delays - United States.

Authors:  Andre F Dailey; Brooke E Hoots; H Irene Hall; Ruiguang Song; Demorah Hayes; Paul Fulton; Joseph Prejean; Angela L Hernandez; Linda J Koenig; Linda A Valleroy
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-12-01       Impact factor: 17.586

View more
  1 in total

1.  State health policies and interest in PrEP: evidence from Google Trends.

Authors:  Bita Fayaz Farkhad; Mohammadreza Nazari; Man-Pui Sally Chan; Dolores Albarracín
Journal:  AIDS Care       Date:  2021-06-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.